Youngeun Lee

Youngeun Lee

Auto-generated profile, based on publicly available information

Youngeun Lee

Department of Laboratory Medicine, Chungbuk National University Hospital, Cheongju, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2024 in Molecular Diagnosis & Therapy
Verified
Journal Article
Open access
PDF file
YLYoungeun Lee
Youngeun Lee
SSSoohyun Seo
Soohyun Seo
JKJinho Kim
Jinho Kim
SKSang-A Kim
Sang-A Kim
JLJi Yun Lee
Ji Yun Lee
SHSang Mee Hwang
Sang Mee Hwang
Introduction Erythrocytosis is attributed to various clinical and molecular factors. Many cases of JAK2-unmutated erythrocytosis remain undiagnosed. We investigated the characteristics and causes of JAK2-unmutated erythrocytosis. Methods We assessed the clinical and laboratory results of patients with erythrocytosis without JAK2 mutations and performed targeted next-generation sequencing (NGS) panels for somatic and germline mutations. Results In total, 117 patients with JAK2-unmutated erythrocytosis were included. The median hemoglobin and hematocrit levels were 17.9 g/dL and 53.4%, respectively. Erythropoietin levels were not below the reference range. Thrombotic events were reported in 17 patients (14.5%). Among JAK2-unmutated patients, 44 had undergone targeted panel sequencing consisting of myeloid neoplasm-related genes, and 16 had one or more reportable variants in ASXL1 (5/44), TET2, CALR, FLT3, and SH2B3 (2/44). Additional testing for germline causes revealed eight variants in seven genes in eight patients, including NF1, BPGM, EPAS1, PIEZO1, RHAG, SH2B3, and VHL genes. One NF1 pathogenic, one BPGM likely pathogenic, and six variants of undetermined significance were detected. Conclusion Somatic and germline mutations were identified in 36.4% and 33.3 % of the JAK2-unmutated group; most variants had unknown clinical significance. Not all genetic causes have been identified; comprehensive diagnostic approaches are crucial for identifying the cause of erythrocytosis.

1 September 2022 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
JLJikyo Lee
Jikyo Lee
SKSung Min Kim
Sung Min Kim
SKSoonok Kim
Soonok Kim
JYJiwon Yun
Jiwon Yun
DJDajeong Jeong
Dajeong Jeong
PHPh.D.
Ph.D.
Jikyo Lee, M.D., Sung Min Kim, B.S., Soonok Kim, M.T., Jiwon Yun, M.D., Dajeong Jeong, M.D., Young Eun Lee, M.D., Eun-Youn Roh, M.D., Ph.D., and Dong Soon Lee, M.D., Ph.D.. Ann Lab Med 2022;42:590-6. https://doi.org/10.3343/alm.2022.42.5.590

1 October 2021 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
YLYoungeun Lee
Youngeun Lee
JYJiwon Yun
Jiwon Yun
DJDajeong Jeong
Dajeong Jeong
SRSohee Ryu
Sohee Ryu
SKSeok Ryun Kwon
Seok Ryun Kwon
DLDong-Soon Lee
Dong-Soon Lee
Plasma cell leukemia (PCL) is clinically and genetically distinct from multiple myeloma (MM), despite controversies regarding the disease definition. To determine the distinct features of PCL, the genetic property of primary PCL (pPCL) was compared with that of secondary PCL (sPCL) and MM. In patients with pPCL, Eighty-nine non-synonymous mutations were observed in 68 genes. The most frequently mutated genes were TP53, TSC2, and TYK2. In comparison with genetic abnormalities of sPCL and MM, 45 genes were present only in pPCL while 28 genes were only in sPCL and 22 genes only in MM. Among the common genes between pPCL and MM, a higher prevalence of TP53 was observed in pPCL, compared to MM (p < 0.05), while similar, compared to sPCL (p = 0.64). In summary, pPCL patients showed a higher level of genetic heterogeneity and distinctive genetic signature in their mutational profile compared to patients with MM and sPCL.


1 May 2022 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
YLYoungeun Lee
Youngeun Lee
HPHyun Jin Park
Hyun Jin Park
HKHyoung Jin Kang
Hyoung Jin Kang
JKJung Min Ko
Jung Min Ko
BKBoram Kim
Boram Kim
PHPh.D.
Ph.D.
Youngeun Lee, M.D., Hyun Jin Park, M.D., Hyoung Jin Kang, M.D., Ph.D., Jung Min Ko, M.D., Ph.D., Boram Kim, M.D., Yoon Hwan Chang, M.D., Ph.D., Hyun Kyung Kim, M.D., Ph.D., Jee-Soo Lee, M.D., Man Jin Kim, M.D., Sung Sup Park, M.D., Ph.D., and Moon-Woo Seong, M.D., Ph.D.. Ann Lab Med 2022;42:384-8. https://doi.org/10.3343/alm.2022.42.3.384

30 June 2025 in Journal of Genetic Medicine
Verified
Journal Article
Open access
PDF file
YLYoungeun Lee
Youngeun Lee
HKHye Ryoun Kim
Hye Ryoun Kim
Youngeun Lee and Hye Ryoun Kim. J Genet Med 2025;22:16-22. https://doi.org/10.5734/JGM.2025.22.1.16